Unrelated Donor Bone Marrow Transplantation for Myelodysplastic Syndrome in Children
Autor(a) principal: | |
---|---|
Data de Publicação: | 2011 |
Outros Autores: | , , , , , , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da UNIFESP |
Texto Completo: | http://repositorio.unifesp.br/handle/11600/33644 http://dx.doi.org/10.1016/j.bbmt.2010.08.016 |
Resumo: | We describe long-term disease-free survival (DFS) after unrelated donor bone marrow transplantation (BMT) for myelodysplastic syndrome (MDS) in <= 8 patients aged years. Forty-six patients had refractory cytopenia (RC), 55 refractory anemia with excess blasts (RAEB), and 17 refractory anemia with excess blasts in transformation (RAEB-t). Transplant-related mortality was higher after mismatched BMT (relative risk [RR] 3.29, P=.002). Disease recurrence was more likely with advanced stages of MDS at the time of BMT: RAEB (RR 6.50, P=.01) or RAEB-t (RR 11.00, P=.004). Treatment failure (recurrent disease or death from any cause; inverse of DFS) occurred in 68 patients. Treatment failure was higher after mismatched BMT (RR 2.79, P=.001) and in those with RAEB-t (RR 2.38, P=.02). Secondary MDS or chemotherapy prior to BMT was not associated with recurrence or treatment failure. Similarly, cytogenetic abnormalities were not associated with transplant outcomes. Eight-year DFS for patients with RC after matched and mismatched unrelated donor BMT was 65% and 40%, respectively. Corresponding DFS for patients with RAEB and RAEB-t was 48% and 28%, respectively. When a matched adult unrelated donor is available, BMT should be offered as first-line therapy, and children with RC can be expected to have the best outcome. Biol Blood Marrow Transplant 17: 723-728 (2011) (C) 2011 American Society for Blood and Marrow Transplantation |
id |
UFSP_5a47734c720efefd0ec3838a32b317d4 |
---|---|
oai_identifier_str |
oai:repositorio.unifesp.br:11600/33644 |
network_acronym_str |
UFSP |
network_name_str |
Repositório Institucional da UNIFESP |
repository_id_str |
3465 |
spelling |
Woodard, PaulCarpenter, Paul A.Davies, Stella M.Gross, Thomas G.He, WenshengZhang, Mei-JieHorn, Biljana N.Margolis, David A.Perentesis, John P.Sanders, Jean E.Schultz, Kirk R.Seber, Adriana [UNIFESP]Woods, William G.Eapen, MaryMed Coll WisconsinAmgen IncFred Hutchinson Canc Res CtrCincinnati Childrens HospNationwide Childrens HospUniv Calif San FranciscoChildrens Hosp WisconsinUBCUniversidade Federal de São Paulo (UNIFESP)Aflac Canc Ctr & Blood Disorders Serv2016-01-24T14:06:25Z2016-01-24T14:06:25Z2011-05-01Biology of Blood and Marrow Transplantation. New York: Elsevier B.V., v. 17, n. 5, p. 723-728, 2011.1083-8791http://repositorio.unifesp.br/handle/11600/33644http://dx.doi.org/10.1016/j.bbmt.2010.08.016WOS000290061500016.pdf10.1016/j.bbmt.2010.08.016WOS:000290061500016We describe long-term disease-free survival (DFS) after unrelated donor bone marrow transplantation (BMT) for myelodysplastic syndrome (MDS) in <= 8 patients aged years. Forty-six patients had refractory cytopenia (RC), 55 refractory anemia with excess blasts (RAEB), and 17 refractory anemia with excess blasts in transformation (RAEB-t). Transplant-related mortality was higher after mismatched BMT (relative risk [RR] 3.29, P=.002). Disease recurrence was more likely with advanced stages of MDS at the time of BMT: RAEB (RR 6.50, P=.01) or RAEB-t (RR 11.00, P=.004). Treatment failure (recurrent disease or death from any cause; inverse of DFS) occurred in 68 patients. Treatment failure was higher after mismatched BMT (RR 2.79, P=.001) and in those with RAEB-t (RR 2.38, P=.02). Secondary MDS or chemotherapy prior to BMT was not associated with recurrence or treatment failure. Similarly, cytogenetic abnormalities were not associated with transplant outcomes. Eight-year DFS for patients with RC after matched and mismatched unrelated donor BMT was 65% and 40%, respectively. Corresponding DFS for patients with RAEB and RAEB-t was 48% and 28%, respectively. When a matched adult unrelated donor is available, BMT should be offered as first-line therapy, and children with RC can be expected to have the best outcome. Biol Blood Marrow Transplant 17: 723-728 (2011) (C) 2011 American Society for Blood and Marrow TransplantationPublic Health Service from National Cancer Institute (NCI)National Heart, Lung and Blood Institute (NHLBI)National Institute of Allergy and Infectious Diseases (NIAID)NHLBINCIHealth Resources and Services Administration (HRSA/DHHS)Office of Naval ResearchAABBAetnaAmerican Society for Blood and Marrow TransplantationAmgen, Inc.Astellas Pharma US, Inc.Baxter International, Inc.Bayer HealthCare PharmaceuticalsBe the Match FoundationBiogen IDECBioMarin Pharmaceutical, Inc.Biovitrum ABBloodCenter of WisconsinBlue Cross and Blue Shield AssociationBone Marrow FoundationBuchanan Family FoundationCanadian Blood and Marrow Transplant GroupCaridianBCTCelgene CorporationCellGenix, GmbHCenters for Disease Control and PreventionChildren's Leukemia Research AssociationClinImmune LabsCTI Clinical Trial and Consulting ServicesCubist PharmaceuticalsCylex Inc.CytoThermDOR BioPharma, Inc.Dynal Biotech, an Invitrogen CompanyEisai, Inc.Enzon Pharmaceuticals, Inc.European Group for Blood and Marrow TransplantationGamida Cell, Ltd.GE HealthcareGenentech, Inc.Genzyme CorporationHistogenetics, Inc.HKS Medical Information SystemsHospira, Inc.Infectious Diseases Society of AmericaKiadis PharmaKirin Brewery Co., Ltd.The Leukemia & Lymphoma SocietyMerck CompanyMedical College of WisconsinMGI Pharma, Inc.Michigan Community Blood CentersMillennium Pharmaceuticals, Inc.Miller Pharmacal GroupMilliman USA, Inc.Miltenyi Biotec, Inc.National Marrow Donor ProgramNature Publishing GroupNew York Blood CenterNovartis OncologyOncology Nursing SocietyOsiris Therapeutics, Inc.Otsuka America Pharmaceutical, Inc.Pall Life SciencesPfizer IncSaladax Biomedical, Inc.Schering CorporationSociety for Healthcare Epidemiology of AmericaSoligenix, Inc.StemCyte, Inc.StemSoft Software, IncSysmex America, Inc.THERAKOS, Inc.Thermogenesis CorporationVidacare CorporationVion Pharmaceuticals, IncViraCor LaboratoriesViroPharma, Inc.Well-point, Inc.Med Coll Wisconsin, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USAAmgen Inc, Thousand Oaks, CA USAFred Hutchinson Canc Res Ctr, Seattle, WA 98104 USACincinnati Childrens Hosp, Med Ctr, Cincinnati, OH USANationwide Childrens Hosp, Columbus, OH USAUniv Calif San Francisco, Med Ctr, San Francisco, CA 94143 USAChildrens Hosp Wisconsin, Milwaukee, WI 53201 USAUBC, British Columbia Childrens Hosp, Vancouver, BC, CanadaInst Oncol Pediat, São Paulo, BrazilAflac Canc Ctr & Blood Disorders Serv, Childrens Healthcare Atlanta Egleston, Atlanta, GA USAUniversidade Federal de São Paulo, EPM, São Paulo, BrazilPublic Health Service from National Cancer Institute (NCI): U24-CA76518NHLBI: 5U01HL069294Health Resources and Services Administration (HRSA/DHHS): HHSH234200637015COffice of Naval Research: N00014-06-1-0704Office of Naval Research: N00014-08-1-0058Web of Science723-728engElsevier B.V.Biology of Blood and Marrow Transplantationhttp://www.elsevier.com/about/open-access/open-access-policies/article-posting-policyinfo:eu-repo/semantics/openAccessPediatric myelodysplastic syndromeUnrelated donorBone marrow transplantationUnrelated Donor Bone Marrow Transplantation for Myelodysplastic Syndrome in Childreninfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articlereponame:Repositório Institucional da UNIFESPinstname:Universidade Federal de São Paulo (UNIFESP)instacron:UNIFESPORIGINALWOS000290061500016.pdfapplication/pdf182280${dspace.ui.url}/bitstream/11600/33644/1/WOS000290061500016.pdfc51a91e18c3515ee1dbd83239a222fdfMD51open accessTEXTWOS000290061500016.pdf.txtWOS000290061500016.pdf.txtExtracted texttext/plain29105${dspace.ui.url}/bitstream/11600/33644/2/WOS000290061500016.pdf.txt345bec723f08ca9651b80443e08eb729MD52open access11600/336442022-11-04 14:18:43.812open accessoai:repositorio.unifesp.br:11600/33644Repositório InstitucionalPUBhttp://www.repositorio.unifesp.br/oai/requestopendoar:34652023-05-25T12:28:33.567683Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)false |
dc.title.en.fl_str_mv |
Unrelated Donor Bone Marrow Transplantation for Myelodysplastic Syndrome in Children |
title |
Unrelated Donor Bone Marrow Transplantation for Myelodysplastic Syndrome in Children |
spellingShingle |
Unrelated Donor Bone Marrow Transplantation for Myelodysplastic Syndrome in Children Woodard, Paul Pediatric myelodysplastic syndrome Unrelated donor Bone marrow transplantation |
title_short |
Unrelated Donor Bone Marrow Transplantation for Myelodysplastic Syndrome in Children |
title_full |
Unrelated Donor Bone Marrow Transplantation for Myelodysplastic Syndrome in Children |
title_fullStr |
Unrelated Donor Bone Marrow Transplantation for Myelodysplastic Syndrome in Children |
title_full_unstemmed |
Unrelated Donor Bone Marrow Transplantation for Myelodysplastic Syndrome in Children |
title_sort |
Unrelated Donor Bone Marrow Transplantation for Myelodysplastic Syndrome in Children |
author |
Woodard, Paul |
author_facet |
Woodard, Paul Carpenter, Paul A. Davies, Stella M. Gross, Thomas G. He, Wensheng Zhang, Mei-Jie Horn, Biljana N. Margolis, David A. Perentesis, John P. Sanders, Jean E. Schultz, Kirk R. Seber, Adriana [UNIFESP] Woods, William G. Eapen, Mary |
author_role |
author |
author2 |
Carpenter, Paul A. Davies, Stella M. Gross, Thomas G. He, Wensheng Zhang, Mei-Jie Horn, Biljana N. Margolis, David A. Perentesis, John P. Sanders, Jean E. Schultz, Kirk R. Seber, Adriana [UNIFESP] Woods, William G. Eapen, Mary |
author2_role |
author author author author author author author author author author author author author |
dc.contributor.institution.none.fl_str_mv |
Med Coll Wisconsin Amgen Inc Fred Hutchinson Canc Res Ctr Cincinnati Childrens Hosp Nationwide Childrens Hosp Univ Calif San Francisco Childrens Hosp Wisconsin UBC Universidade Federal de São Paulo (UNIFESP) Aflac Canc Ctr & Blood Disorders Serv |
dc.contributor.author.fl_str_mv |
Woodard, Paul Carpenter, Paul A. Davies, Stella M. Gross, Thomas G. He, Wensheng Zhang, Mei-Jie Horn, Biljana N. Margolis, David A. Perentesis, John P. Sanders, Jean E. Schultz, Kirk R. Seber, Adriana [UNIFESP] Woods, William G. Eapen, Mary |
dc.subject.eng.fl_str_mv |
Pediatric myelodysplastic syndrome Unrelated donor Bone marrow transplantation |
topic |
Pediatric myelodysplastic syndrome Unrelated donor Bone marrow transplantation |
description |
We describe long-term disease-free survival (DFS) after unrelated donor bone marrow transplantation (BMT) for myelodysplastic syndrome (MDS) in <= 8 patients aged years. Forty-six patients had refractory cytopenia (RC), 55 refractory anemia with excess blasts (RAEB), and 17 refractory anemia with excess blasts in transformation (RAEB-t). Transplant-related mortality was higher after mismatched BMT (relative risk [RR] 3.29, P=.002). Disease recurrence was more likely with advanced stages of MDS at the time of BMT: RAEB (RR 6.50, P=.01) or RAEB-t (RR 11.00, P=.004). Treatment failure (recurrent disease or death from any cause; inverse of DFS) occurred in 68 patients. Treatment failure was higher after mismatched BMT (RR 2.79, P=.001) and in those with RAEB-t (RR 2.38, P=.02). Secondary MDS or chemotherapy prior to BMT was not associated with recurrence or treatment failure. Similarly, cytogenetic abnormalities were not associated with transplant outcomes. Eight-year DFS for patients with RC after matched and mismatched unrelated donor BMT was 65% and 40%, respectively. Corresponding DFS for patients with RAEB and RAEB-t was 48% and 28%, respectively. When a matched adult unrelated donor is available, BMT should be offered as first-line therapy, and children with RC can be expected to have the best outcome. Biol Blood Marrow Transplant 17: 723-728 (2011) (C) 2011 American Society for Blood and Marrow Transplantation |
publishDate |
2011 |
dc.date.issued.fl_str_mv |
2011-05-01 |
dc.date.accessioned.fl_str_mv |
2016-01-24T14:06:25Z |
dc.date.available.fl_str_mv |
2016-01-24T14:06:25Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.citation.fl_str_mv |
Biology of Blood and Marrow Transplantation. New York: Elsevier B.V., v. 17, n. 5, p. 723-728, 2011. |
dc.identifier.uri.fl_str_mv |
http://repositorio.unifesp.br/handle/11600/33644 http://dx.doi.org/10.1016/j.bbmt.2010.08.016 |
dc.identifier.issn.none.fl_str_mv |
1083-8791 |
dc.identifier.file.none.fl_str_mv |
WOS000290061500016.pdf |
dc.identifier.doi.none.fl_str_mv |
10.1016/j.bbmt.2010.08.016 |
dc.identifier.wos.none.fl_str_mv |
WOS:000290061500016 |
identifier_str_mv |
Biology of Blood and Marrow Transplantation. New York: Elsevier B.V., v. 17, n. 5, p. 723-728, 2011. 1083-8791 WOS000290061500016.pdf 10.1016/j.bbmt.2010.08.016 WOS:000290061500016 |
url |
http://repositorio.unifesp.br/handle/11600/33644 http://dx.doi.org/10.1016/j.bbmt.2010.08.016 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.ispartof.none.fl_str_mv |
Biology of Blood and Marrow Transplantation |
dc.rights.driver.fl_str_mv |
http://www.elsevier.com/about/open-access/open-access-policies/article-posting-policy info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
http://www.elsevier.com/about/open-access/open-access-policies/article-posting-policy |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
723-728 |
dc.publisher.none.fl_str_mv |
Elsevier B.V. |
publisher.none.fl_str_mv |
Elsevier B.V. |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UNIFESP instname:Universidade Federal de São Paulo (UNIFESP) instacron:UNIFESP |
instname_str |
Universidade Federal de São Paulo (UNIFESP) |
instacron_str |
UNIFESP |
institution |
UNIFESP |
reponame_str |
Repositório Institucional da UNIFESP |
collection |
Repositório Institucional da UNIFESP |
bitstream.url.fl_str_mv |
${dspace.ui.url}/bitstream/11600/33644/1/WOS000290061500016.pdf ${dspace.ui.url}/bitstream/11600/33644/2/WOS000290061500016.pdf.txt |
bitstream.checksum.fl_str_mv |
c51a91e18c3515ee1dbd83239a222fdf 345bec723f08ca9651b80443e08eb729 |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 |
repository.name.fl_str_mv |
Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP) |
repository.mail.fl_str_mv |
|
_version_ |
1783460238253359104 |